March 1, 2017

FLG client GRAIL, Inc., a life sciences company whose mission is to detect cancer early when it can be cured, today announced that it has raised over $900 million through the first close of its previously announced Series B financing which was led by ARCH Venture Partners and includes Johnson & Johnson Innovation as the largest investor in the financing. GRAIL plans a second close with institutional investors to bring the total raised in the Series B to over $1 billion. Company press release. FLG partner: Mark Murray.